{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:49Z","timestamp":1789011589980,"version":"build-2803163510"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1212\/con.0000000000000241","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T04:34:17Z","timestamp":1449203657000},"page":"1662-1678","source":"Crossref","is-referenced-by-count":37,"title":["Fungal Infections of the Central Nervous System"],"prefix":"10.1212","volume":"21","author":[{"given":"Anil A.","family":"Panackal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Murthy JM Sundaram C. Fungal infections of the central nervous system. Handb Clin Neurol 2014; 121: 1383\u20131401. doi:10.1016\/B978-0-7020-4088-7.00095-X.","DOI":"10.1016\/B978-0-7020-4088-7.00095-X"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Datta K Bartlett KH Baer R et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis 2009; 15 (8): 1185\u20131191. doi:10.3201\/eid1508.081384.","DOI":"10.3201\/eid1508.081384"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Smith RM Schaefer MK Kainer MA et al. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med 2013; 369 (17): 1598\u20131609. doi:10.1056\/NEJMoa1213978.","DOI":"10.1056\/NEJMoa1213978"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","unstructured":"Park BJ Wannemuehler KA Marston BJ et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS. AIDS 2009; 23 (4): 525\u2013530. doi:10.1097\/QAD.0b013e328322ffac.","DOI":"10.1097\/QAD.0b013e328322ffac"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Pyrgos V Seitz AE Steiner CA et al. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One 2013; 8 (2): e56269. doi:10.1371\/journal.pone.0056269.","DOI":"10.1371\/journal.pone.0056269"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Pappas PG Alexander BD Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50 (8): 1101\u20131111. doi:10.1086\/651262.","DOI":"10.1086\/651262"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Neofytos D Fishman JA Horn D et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12 (3): 220\u2013229. doi:10.1111\/j.1399-3062.2010.00492.x.","DOI":"10.1111\/j.1399-3062.2010.00492.x"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Bratton EW El Husseini N Chastain CA et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected solid organ transplant and HIV-negative\/non-transplant. PLoS One 2012; 7 (8): e43582. doi:10.1371\/journal.pone.0043582.","DOI":"10.1371\/journal.pone.0043582"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Brizendine KD Baddley JW Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One 2013; 8 (3): e60431. doi:10.1371\/journal.pone.0060431.","DOI":"10.1371\/journal.pone.0060431"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Harris JR Lockhart SR Debess E et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53 (12): 1188\u20131195. doi:10.1093\/cid\/cir723.","DOI":"10.1093\/cid\/cir723"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Chen SCA Slavin MA Heath CH et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012; 55 (6): 789\u2013798. doi:10.1093\/cid\/cis529.","DOI":"10.1093\/cid\/cis529"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Chen SC Korman TM Slavin MA et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis 2013; 57 (4): 543\u2013551. doi:10.1093\/cid\/cit341.","DOI":"10.1093\/cid\/cit341"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Saijo T Chen J Chen SC et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. MBio 2014; 5 (2): e00912\u2013e00914. doi:10.1128\/mBio.00912-14.","DOI":"10.1128\/mBio.00912-14"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Bicanic T Harrison TS. Cryptococcal meningitis. Br Med Bull 2005; 72: 99\u2013118. doi:10.1093\/bmb\/ldh043.","DOI":"10.1093\/bmb\/ldh043"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Jarvis JN Bicanic T Loyse A et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014; 58 (5): 736\u2013745. doi:10.1093\/cid\/cit794.","DOI":"10.1093\/cid\/cit794"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Panackal AA Dekker JP Proschan M et al. Enzyme immunoassay versus latex agglutination cryptococcal antigen assays in adults with non-HIV-related cryptococcosis. J Clin Microbiol 2014; 52 (12): 4356\u20134358. doi:10.1128\/JCM.02017-14.","DOI":"10.1128\/JCM.02017-14"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Starkey J Moritani T Kirby P. MRI of CNS fungal infections: review of aspergillosis to histoplasmosis and everything in between. Clin Neuroradiol 2014; 24 (3): 217\u2013230. doi:10.1007\/s00062-014-0305-7.","DOI":"10.1007\/s00062-014-0305-7"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Hansen J Slechta ES Gates-Hollingsworth MA et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol 2013; 20 (1): 52\u201355. doi:10.1128\/CVI.00536-12.","DOI":"10.1128\/CVI.00536-12"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Bicanic T Meintjes G Wood R et al. Fungal burden early fungicidal activity and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45 (1): 76\u201380. doi:10.1086\/518607.","DOI":"10.1086\/518607"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Perfect JR Dismukes WE Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (3): 291\u2013322. doi:10.1086\/649858.","DOI":"10.1086\/649858"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Pascual A Calandra T Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46 (2): 201\u2013211. doi:10.1086\/524669.","DOI":"10.1086\/524669"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Rosen LB Freeman AF Yang LM et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 2013; 190 (8): 3959\u20133966. doi:10.4049\/jimmunol.1202526.","DOI":"10.4049\/jimmunol.1202526"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Haddow LJ Colebunders R Meintjes G et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10 (11): 791\u2013802. doi:10.1016\/S1473-3099(10)70170-5.","DOI":"10.1016\/S1473-3099(10)70170-5"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Singh N Lortholary O Alexander BD et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40 (12): 1756\u20131761. doi:10.1086\/430606.","DOI":"10.1086\/430606"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Panackal AA Wuest SC Lin YC et al. Paradoxical immune responses in non-HIV cryptococcal meningitis. PLoS Pathog 2015; 11: e1004884. doi:10.1371\/journal.ppat.1004884.","DOI":"10.1371\/journal.ppat.1004884"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","unstructured":"Johnson T Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 2011; 24 (3): 284\u2013290. doi:10.1097\/WCO.0b013e328346be57.","DOI":"10.1097\/WCO.0b013e328346be57"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Newton PN Thai le H Tip NQ et al. A randomized double-blind placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35 (6): 769\u2013772. doi:10.1086\/342299.","DOI":"10.1086\/342299"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Guimara\u02dces AJ Frases S Cordero RJ et al. Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell Microbiol 2010; 12 (6): 740\u2013753. doi:10.1111\/j.1462-5822.2010.01430.x.","DOI":"10.1111\/j.1462-5822.2010.01430.x"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005; 40 (3): 480\u2013482. doi:10.1086\/427222.","DOI":"10.1086\/427222"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Pfaller MA Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20 (1): 133\u2013163. doi:10.1128\/CMR.00029-06.","DOI":"10.1128\/CMR.00029-06"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Lipton SA Hickey WF Morris JH Loscalzo J. Candidal infection in the central nervous system. Am J Med 1984; 76 (1): 101\u2013108. doi:10.1016\/0002-9343(84)90757-5.","DOI":"10.1016\/0002-9343(84)90757-5"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Gavino C Cotter A Lichtenstein D et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy. Clin Infect Dis 2014; 59 (1): 81\u201384. doi:10.1093\/cid\/ciu215.","DOI":"10.1093\/cid\/ciu215"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Pappas PG Kauffman CA Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (5): 503\u2013535. doi:10.1086\/596757.","DOI":"10.1086\/596757"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 1984; 105 (4): 616\u2013622. doi:10.1016\/S0022-3476(84)80433-3.","DOI":"10.1016\/S0022-3476(84)80433-3"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Burgert SJ Classen DC Burke JP Blatter DD. Candidal brain abscess associated with vascular invasion: a devastating complication of vascular catheter-related candidemia. Clin Infect Dis 1995; 21 (1): 202\u2013205. doi:10.1093\/clinids\/21.1.202.","DOI":"10.1093\/clinids\/21.1.202"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","unstructured":"Voice RA Bradley SF Sangeorzan JA Kauffman CA. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994; 19 (1): 60\u201366. doi:10.1093\/clinids\/19.1.60.","DOI":"10.1093\/clinids\/19.1.60"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Lyons JL Erkkinen MG Vodopivec I. Cerebrospinal fluid (1 3)-\u03b2-D-glucan in isolated candida meningitis. Clin Infect Dis 2015; 60 (1): 161\u2013162. doi:10.1093\/cid\/ciu737.","DOI":"10.1093\/cid\/ciu737"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Litvintseva AP Lindsley MD Gade L et al. Utility of (1-3)-\u03b2-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections. Clin Infect Dis 2014; 58 (5): 622\u2013630. doi:10.1093\/cid\/cit808.","DOI":"10.1093\/cid\/cit808"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Lewis JS 2nd Graybill JR. Fungicidal versus Fungistatic: what\u2019s in a word? Expert Opin Pharmacother 2008; 9 (6): 927\u2013935. doi:10.1517\/14656566.9.6.927.","DOI":"10.1517\/14656566.9.6.927"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Kethireddy S Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 2007; 3 (4): 573\u2013581. doi:10.1517\/17425255.3.4.573.","DOI":"10.1517\/17425225.3.4.573"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Panackal AA Gribskov JL Staab JF et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44 (5): 1740\u20131743. doi:10.1128\/JCM.44.5.1740-1743.2006.","DOI":"10.1128\/JCM.44.5.1740-1743.2006"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Panackal AA Bennett JE Williamson PR. Treatment options in invasive aspergillosis. Curr Treat Options Infect Dis 2014; 6 (3): 309\u2013325. doi:10.1007\/s40506-014-0016-2.","DOI":"10.1007\/s40506-014-0016-2"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"Song E Jaishankar GB Saleh H et al. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy 2011; 9 (1): 10. doi:10.1186\/1476-7961-9-10.","DOI":"10.1186\/1476-7961-9-10"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Kourkoumpetis TK Desalermos A Muhammed M Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore) 2012; 91 (6): 328\u2013336. doi:10.1097\/MD.0b013e318274cd77.","DOI":"10.1097\/MD.0b013e318274cd77"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","unstructured":"Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo) 2013; 2013: 459405. doi:10.1155\/2013\/459405.","DOI":"10.1155\/2013\/459405"},{"key":"e_1_3_1_53_2","doi-asserted-by":"crossref","unstructured":"Gabelmann A Klein S Kern W et al. Relevant imaging findings of cerebral aspergillosis on MRI: a retrospective case-based study in immunocompromised patients. Eur J Neurol 2007; 14 (5): 548\u2013555. doi:10.1111\/j.1468-1331.2007.01755.x.","DOI":"10.1111\/j.1468-1331.2007.01755.x"},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","unstructured":"Schwartz S Ruhnke M Ribaud P et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood 2005; 106 (8): 2641\u20132645. doi:10.1182\/blood-2005-02-0733.","DOI":"10.1182\/blood-2005-02-0733"},{"key":"e_1_3_1_55_2","doi-asserted-by":"crossref","unstructured":"Schwartz S Reisman A Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection 2011; 39 (3): 201\u2013210. doi:10.1007\/s15010-011-0108-6.","DOI":"10.1007\/s15010-011-0108-6"},{"key":"e_1_3_1_56_2","doi-asserted-by":"crossref","unstructured":"Walsh TJ Anaissie EJ Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3): 327\u2013360. doi:10.1086\/525258.","DOI":"10.1086\/525258"},{"key":"e_1_3_1_57_2","doi-asserted-by":"crossref","unstructured":"Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54 (suppl 1): S8\u2013S15. doi:10.1093\/cid\/cir864.","DOI":"10.1093\/cid\/cir864"},{"key":"e_1_3_1_58_2","doi-asserted-by":"crossref","unstructured":"Chamilos G Lewis RE Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47 (4): 503\u2013509. doi:10.1086\/590004.","DOI":"10.1086\/590004"},{"key":"e_1_3_1_59_2","doi-asserted-by":"crossref","unstructured":"Lass-Florl C Resch G Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45 (7): e101\u2013e104. doi:10.1086\/521245.","DOI":"10.1086\/521245"},{"key":"e_1_3_1_60_2","doi-asserted-by":"crossref","unstructured":"Garcia-Vidal C Upton A Kirby KA Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47 (8): 1041\u20131050. doi:10.1086\/591969.","DOI":"10.1086\/591969"},{"key":"e_1_3_1_61_2","doi-asserted-by":"crossref","unstructured":"Petrikkos G Skiada A Lortholary O et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (suppl 1): S23\u2013S34. doi:10.1093\/cid\/cir866.","DOI":"10.1093\/cid\/cir866"},{"key":"e_1_3_1_62_2","doi-asserted-by":"crossref","unstructured":"Vehreschild JJ Birtel A Vehreschild MJ et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013; 39 (3): 310\u2013324. doi:10.3109\/1040841X.2012.711741.","DOI":"10.3109\/1040841X.2012.711741"},{"key":"e_1_3_1_63_2","doi-asserted-by":"crossref","unstructured":"Ben-Ami R Luna M Lewis RE et al. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect 2009; 59 (2): 134\u2013138. doi:10.1016\/j.jinf.2009.06.002.","DOI":"10.1016\/j.jinf.2009.06.002"},{"key":"e_1_3_1_64_2","doi-asserted-by":"crossref","unstructured":"Kontoyiannis DP Lewis RE. How I treat mucormycosis. Blood 2011; 118 (5): 1216\u20131224. doi:10.1182\/blood-2011-03-316430.","DOI":"10.1182\/blood-2011-03-316430"},{"key":"e_1_3_1_65_2","doi-asserted-by":"crossref","unstructured":"Revankar SG Sutton DA Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38 (2): 206\u2013216. doi:10.1086\/380635.","DOI":"10.1086\/380635"},{"key":"e_1_3_1_66_2","unstructured":"65. Centers for Disease Control and Prevention. Multistate outbreak of fungal meningitis and other infections. www.cdc.gov\/hai\/outbreaks\/meningitis.html. Updated October 23 2013. Accessed October 2 2015."},{"key":"e_1_3_1_67_2","doi-asserted-by":"crossref","unstructured":"Chiller TM Roy M Nguyen D et al. Clinical findings for fungal infections caused by methylprednisolone injections. N Engl J Med 2013; 369 (17): 1610\u20131619. doi:10.1056\/NEJMoa1304879.","DOI":"10.1056\/NEJMoa1304879"},{"key":"e_1_3_1_68_2","doi-asserted-by":"crossref","unstructured":"Pappas PG. Lessons learned in the multistate fungal infection outbreak in the United States. Curr Opin Infect Dis 2013; 26 (6): 545\u2013550. doi:10.1097\/QCO.0000000000000013.","DOI":"10.1097\/QCO.0000000000000013"},{"key":"e_1_3_1_69_2","unstructured":"68. Centers for Disease Control and Prevention. Multistate outbreak of fungal meningitis and other infections\u2014resources for laboratories. www.cdc.gov\/hai\/outbreaks\/laboratory\/index.html. Updated May 19 2014. Accessed October 2 2015."},{"key":"e_1_3_1_70_2","doi-asserted-by":"crossref","unstructured":"Kantarcioglu AS Guarro J de Hoog GS. Central nervous system infections by members of the Pseudallescheria boydii species complex in healthy and immunocompromised hosts: epidemiology clinical characteristics and outcome. Mycoses 2008; 51 (4): 275\u2013290. doi:10.1111\/j.1439-0507.2008.01489.x.","DOI":"10.1111\/j.1439-0507.2008.01489.x"},{"key":"e_1_3_1_71_2","doi-asserted-by":"crossref","unstructured":"Cortez KJ Roilides E Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21 (1): 157\u2013197. doi:10.1128\/CMR.00039-07.","DOI":"10.1128\/CMR.00039-07"},{"key":"e_1_3_1_72_2","doi-asserted-by":"crossref","unstructured":"Smith JA Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs 2009; 69 (11): 1403\u20131415. doi:10.2165\/00003495-200969110-00001.","DOI":"10.2165\/00003495-200969110-00002"},{"key":"e_1_3_1_73_2","doi-asserted-by":"crossref","unstructured":"Mathisen G Shelub A Truong J Wigen C. Coccidioidal meningitis: clinical presentation and management in the fluconazole era. Medicine (Baltimore) 2010; 89 (5): 251\u2013284. doi:10.1097\/MD.0b013e3181f378a8.","DOI":"10.1097\/MD.0b013e3181f378a8"},{"key":"e_1_3_1_74_2","doi-asserted-by":"crossref","unstructured":"Lammering JC Iv M Gupta N et al. Imaging spectrum of CNS coccidioidomycosis: prevalence and significance of concurrent brain and spinal disease. AJR Am J Roentgenol 2013; 200 (6): 1334\u20131346. doi:10.2214\/AJR.12.9264.","DOI":"10.2214\/AJR.12.9264"},{"key":"e_1_3_1_75_2","doi-asserted-by":"crossref","unstructured":"Galgiani JN Catanzaro A Cloud GA et al.; NIAID-Mycoses Study Group. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993; 119 (1): 28\u201335.","DOI":"10.7326\/0003-4819-119-1-199307010-00005"},{"key":"e_1_3_1_76_2","doi-asserted-by":"crossref","unstructured":"Galgiani JN Ampel NM Blair JE et al. Coccidioidomycosis. Clin Infect Dis 2005; 41 (9): 1217\u20131223. doi:10.1086\/496991.","DOI":"10.1086\/496991"},{"key":"e_1_3_1_77_2","doi-asserted-by":"crossref","unstructured":"Dewsnup DH Galgiani JN Graybill JR et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996; 124 (3): 305\u2013310.","DOI":"10.7326\/0003-4819-124-3-199602010-00004"},{"key":"e_1_3_1_78_2","doi-asserted-by":"crossref","unstructured":"Wheat LJ Musial CE Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005; 40 (6): 844\u2013852. doi:10.1086\/427880.","DOI":"10.1086\/427880"},{"key":"e_1_3_1_79_2","doi-asserted-by":"crossref","unstructured":"Saccente M. Central nervous system histoplasmosis. Curr Treat Options Neurol 2008; 10 (3): 161\u2013167. doi:10.1007\/s11940-008-0017-x.","DOI":"10.1007\/s11940-008-0017-x"},{"key":"e_1_3_1_80_2","doi-asserted-by":"crossref","unstructured":"Nguyen FN Kar JK Zakaria A Schiess MC. Isolated central nervous system histoplasmosis presenting with ischemic pontine stroke and meningitis in an immune-competent patient. JAMA Neurol 2013; 70 (5): 638\u2013641. doi:10.1001\/jamaneurol.2013.1043.","DOI":"10.1001\/jamaneurol.2013.1043"},{"key":"e_1_3_1_82_2","doi-asserted-by":"crossref","unstructured":"Myint T Anderson AM Sanchez A et al. Histoplasmosis in patients with human immunodeficiency virus\/acquired immunodeficiency syndrome (HIV\/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore) 2014; 93 (1): 11\u201318. doi:10.1097\/MD.0000000000000016.","DOI":"10.1097\/MD.0000000000000016"},{"key":"e_1_3_1_83_2","doi-asserted-by":"crossref","unstructured":"Chapman SW Dismukes WE Proia LA et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (12): 1801\u20131812. doi:10.1086\/588300.","DOI":"10.1086\/588300"},{"key":"e_1_3_1_84_2","doi-asserted-by":"crossref","unstructured":"Bariola JR Perry P Pappas PG et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 2010; 50 (6): 797\u2013804. doi:10.1086\/650579.","DOI":"10.1086\/650579"},{"key":"e_1_3_1_85_2","doi-asserted-by":"crossref","unstructured":"Saccente M Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev 2010; 23 (2): 367\u2013381. doi:10.1128\/CMR.00056-09.","DOI":"10.1128\/CMR.00056-09"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/CON.0000000000000241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:09:41Z","timestamp":1752156581000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1212\/CON.0000000000000241"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000241","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}